SYD985 is another HER2 ADC, consisting of trastuzumab conjugated to a duocarmycin-based payload (T-Duo) via a cleavable valine-alanine linker, which remains stable in circulation but is selectively cleaved by tumor-associated proteases. This evidence concerns the gene ERBB2 and neoplasm.